Immune checkpoint inhibitors have revolutionised cancer therapy, for example in the treatment of malignant melanoma. Unfortunately, the use of these agents is associated with many immune-related adverse events (irAEs).
In general, cutaneous toxicity is a predictive biomarker for clinical outcome in patients receiving anticancer therapy . There is a clear association between cutaneous toxicity and efficacy of treatment not only with immunotherapy, but also in targeted therapy and cytotoxic chemotherapeutics.
Anti-programmed cell death receptor-1 (PD-1) antibodies act via blockade of the PD-1 receptor, an inhibitor of the T cell effector mechanisms that limit immune responses against tumours. “IrAEs may involve numerous organ systems, but mainly the skin,” said Prof. Jennifer N. Choi (Northwestern Feinberg School of Medicine, USA) . Of irAEs related to checkpoint inhibitors, 30-40% are cutaneous side effects . Approximately 30% of patients su...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Combinations are hot in AD treatment Next Article
Novel lupus classification will aid future research »
Table of Contents: WCD 2019
Treating Psoriasis in 2019
Atopic Dermatitis – What is New
Dermal Reactions to Systemic Drugs
Lupus Erythematosus Today
Small Molecules – What to Expect
Optimising the Management of Keloids
Malignant Melanoma – Advances in Management
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.